ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 12, 2022 10:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority
SYDNEY, AU, Oct 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has again received "Best Workplace" certification by the leading workplace culture organization Great Place to Work Institute. Novotech's India team has received a Best Workplaces for Women 2022 recognition and listed in the Top 75 organisations in India recognised for excelling people practices, responsiveness to feedback and a culture of openness and diversity. Novotech also holds Great Place to Workplace recognition in Australia and Korea.
To identify India's Best Workplaces for Women 2022, Great Place to Work India studied 1122 organizations that had:
- Women employees constituting at least 10% of their workforce
- Women employees sharing at least 70% positive feedback on the Great Place to Work Trust Index Organizations that excelled in gender parity in representation
According to Great Place to Work India: "We have observed that the Best Workplaces have gone above and beyond to create and sustain aspirational organizations. We congratulate Novotech for being a role-model in India by fostering an equal and equitable workplace culture."
Novotech CEO Dr. John Moller said: "As a leading employer of women in India we are extremely pleased to be ranked among the top companies in India as a Best Workplaces for Women 2022. This is especially important for retaining and attracting top talent. This recognition demonstrates the importance of culture, diversity and work life balance as we strive to be one of the leading employers so we can deliver our world-class CRO services across India."
Novotech's Chief People Officer Angela Edwardson said: "We are delighted that Novotech India has been recognized as a leading employer for women. This is a real credit to our workplace culture and leadership that drives all our Asia Pacific and North American teams. Novotech attracts a high proportion of talented female employees, so we are extremely proud to have our workplace recognized using the criteria from the Great Place to Work Institute's Trust Index and the Gender Parity in Experience & Representation. Our continued focus on building a leading workplace means team members can balance their personal responsibilities with work during all stages of life."
According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Employees are the most valuable assets of a company. Novotech is dedicated to improving our working environment and enhance employee health and wellbeing. We are more than grateful to receive this recognition."
Sridevi Gubbala, Manager Centralized Document Management Novotech said: "Novotech is a great place to work. It's wonderful to have flexibility at work because it helps me balance my work and personal life."
Vandana Jaising, Manager Project Support joined Novotech after an extended career break and said: "Women should consider coming back, even if it is has been a while. Before joining Novotech I took an eight-year career break, and now I'm glad Novotech had the confidence in me to say 'YES! You can do it!'"
Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.
About Novotech
Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
Fujitsu collaborates with global suppliers in decarbonization initiative to exchange product-level primary data on CO2 emissions
Nov 15, 2024 10:13 JST
TANAKA Successfully Develops the World's First[1] Manufacturing Technology for Platinum Materials with Nano-Sized Crystal Grains
Nov 15, 2024 04:00 JST
myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth
Nov 14, 2024 20:00 JST
ULVAC Launches Oil Rotary Vacuum Pump Gv135
Nov 14, 2024 10:00 JST
MHI Publishes MHI REPORT 2024
Nov 13, 2024 16:52 JST
SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization
Nov 13, 2024 12:38 JST
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 12:05 JST
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 13, 2024 11:16 JST
All-New Triton Wins Special Award at the RJC Car of the Year for 2025
Nov 12, 2024 22:09 JST
Toyota: HySE to participate in the Dakar 2025 "Mission 1000 ACT2" with the HySE-X2, to tackle further technical challenges
Nov 12, 2024 20:04 JST
NEC participates in COP29 climate change conference
Nov 12, 2024 19:25 JST
JA Mitsui Leasing and Fujitsu collaborate on simulation-driven field trials to optimize commercial EV adoption and drive decarbonization
Nov 12, 2024 13:57 JST
Macnica publishes Integrated Report on the theme of 'An Introductory Guide to Macnica's Mechanism'
Nov 12, 2024 13:00 JST
Hitachi: Established the Open Source Program Office (OSPO) to Globally Lead the Strategic Utilization of OSS
Nov 11, 2024 10:31 JST
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Nov 08, 2024 10:31 JST
Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 07, 2024 18:19 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>